“About time for precision immunotherapy”. As an MRK / BMY shareholder I’ve stated I would expect both to exhaust all non-autologous alternatives for CI combos before embarking the autologous combination route ……CI targeting has been somewhat scattered to date. Perhaps it’s about time to dial in a little more precision in targeting???
News 
Market Data 
Discover 
